Loading
Life sciences · Journal article
Diagnostics · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Although evaluating coronary flow velocity reserve (CFVR) via stress echocardiography (SE) has been available for over three decades, its integration into routine clinical practice remains underutilized globally despite substantial technical and conceptual advances. A diminished CFVR serves as a potent predictor of major adverse cardiovascular events (MACE) and all-cause mortality across a broad spectrum of cardiovascular diseases. Its prognostic value is particularly robust in epicardial coronary artery disease, heart failure, coronary microvascular dysfunction, nonischemic cardiomyopathies, metabolic disorders (e.g., diabetes mellitus and obesity), hypertrophic cardiomyopathy, systemic autoimmune diseases, and cardiac allograft vasculopathy. This comprehensive narrative review details the technical methodology for interrogating resting and stress-induced coronary flow velocity (CFV) under physical and pharmacological protocols. Furthermore, it highlights the clinical applicability of CFVR by synthesizing single-center observational insights with evidence from large-scale multicenter registries, advocating for its broader adoption into diagnostic workflows to refine risk stratification and guide therapeutic management.